Genital Diseases, Female  >>  Vectibix (panitumumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Vectibix (panitumumab) / Amgen
PaLiDo, NCT00861120 / 2008-007799-13: Panitumumab and Pegylated Liposomal Doxorubicin for Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-type

Checkmark P2 data
Dec 2012 - Dec 2012: P2 data
Checkmark P2 data - ASCO
Jun 2012 - Jun 2012: P2 data - ASCO
Completed
2
33
Europe
Pegylated liposomal doxorubicin, Caelyx, Panitumumab, Vectibix
Vejle Hospital
Epithelial Ovarian Cancer
08/11
08/12
PanGem, NCT01296035: Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

Terminated
2
8
US
Panitumumab
Women and Infants Hospital of Rhode Island, Amgen
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
10/13
11/13

Download Options